Preparation method of balloon with near-infrared response, efficient delivery and controllable drug release functions
By forming a polydopamine and lauric acid coating on the surface of the drug balloon and combining drug-loaded nanoparticles, the problem of falling off and losing the drug balloon during the push process is solved, and efficient delivery and controlled release of the drug are achieved.
Patent Information
- Application Number
- CN202411141049.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The drug coating is prone to fall off and lose due to insufficient adhesion during the push of the drug balloon, making it difficult for the drug to be completely released on the blood vessel wall.
By forming a polydopamine coating on the balloon surface and covering it with lauric acid and drug-loaded nanoparticles, the adhesion properties of polydopamine and the phase change properties of lauric acid are utilized to achieve efficient delivery and controlled release of drugs.
Zero loss of drugs and controllable complete release are achieved, which improves drug delivery efficiency and reduces the rate of drug shedding in the vascular lumen.
Smart Images

Figure CN119015518A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of interventional medical devices, and in particular relates to a method for preparing a balloon capable of near-infrared response, efficient delivery and controllable release of drugs. Background Art
[0002] Drug-coated balloons are one of the effective methods for treating atherosclerotic stenosis. The anti-proliferative drugs contained in the surface coating adhere to the blood vessel wall and inhibit the re-growth of the vascular intima. In order to transfer as much drug sprayed on the balloon surface as possible to the blood vessel wall, the adhesion between the drug coating and the balloon should not be too strong.
[0003] However, since the drug-coated balloon is subject to friction resistance and blood flow impact during its push into the blood vessel cavity, the drug coating is prone to fall off and loss to varying degrees due to insufficient adhesion. Summary of the invention
[0004] The purpose of the present invention is to provide a method for preparing a balloon with near-infrared response, efficient delivery and controllable release of drugs. By modifying the balloon, it has the characteristics of zero drug loss and controllable complete release, thereby solving the problems of high drug loss rate and difficulty in targeted complete release of traditional drug balloons.
[0005] To achieve the above objectives, the present invention provides, on one hand, a balloon with near-infrared response, efficient drug delivery and controllable drug release, comprising a base balloon; the surface of the balloon has a coating formed of polydopamine, and the polydopamine coating is formed on the surface of the balloon by an oxidative self-polymerization reaction; the polydopamine coating is further covered with a phase change material lauric acid; drug-loaded nanoparticles are adhered to the lauric acid, and the drug-loaded nanoparticles are wrapped by polydopamine.
[0006] Another aspect of the present invention provides a method for preparing a balloon having near infrared response, efficient delivery and controllable release of drugs, comprising the following steps:
[0007] S1: Take Tris-HCl buffer solution, add dopamine hydrochloride, then put in the balloon and stir, wash with ethanol and freeze-dry to obtain a polydopamine coated balloon; S2: Take anhydrous ethanol and add lauric acid, then add the polydopamine-coated balloon and stir to obtain a lauric acid-polydopamine balloon; S3: The polydopamine-coated drug-loaded nanoparticles are adhered to the outermost layer of the lauric acid-polydopamine balloon by dip coating.
[0008] Preferably, in S1, the Tris-HCl buffer solution is 19-21 ml.
[0009] Preferably, in S1, the Tris-HCl buffer solution is 9-11 mM, pH=8.5.
[0010] Preferably, in S1, the amount of dopamine hydrochloride is 50-70 mg.
[0011] Preferably, in S1, the stirring condition is stirring in the dark for 23-25 hours.
[0012] Preferably, in S1, the number of ethanol washings is 3 times.
[0013] Preferably, in S2, the amount of anhydrous ethanol is 19-21 ml.
[0014] Preferably, in S2, lauric acid is 199-201 mg.
[0015] Preferably, in S2, the stirring condition is stirring at room temperature for 23-25 hours.
[0016] Technical effects and advantages of the present invention: The present invention provides a method for preparing a balloon with near-infrared response, efficient delivery and controlled release of drugs, which has the following advantages over the prior art:
[0017] The present invention modifies the traditional drug balloon by using highly biocompatible materials polydopamine and lauric acid, and attaches polydopamine, lauric acid and drug-loaded nanoparticles layer by layer on the balloon surface. Among them, polydopamine is the main component of the sticky protein of mussel byssus, and has extremely strong adhesion properties; the phase change material lauric acid falls off from the balloon surface after being heated, and the balloon is modified to have the characteristics of zero drug loss and controllable complete release. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 is a scanning electron microscope image of the balloon of the present invention;
[0019] Figure 2 This is a photothermal performance diagram of the present invention under near-infrared light conditions;
[0020] Figure 3 It is a curve diagram of the photothermal performance of the present invention. DETAILED DESCRIPTION
[0021] The following will be combined with the accompanying drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. The specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0022] Example 1
[0023] This embodiment provides a balloon with near infrared response, efficient delivery and controlled release of drugs.
[0024] The invention comprises a base balloon; the surface of the balloon has a coating formed of polydopamine, and the polydopamine coating is formed on the surface of the balloon through an oxidative self-polymerization reaction; the polydopamine coating is further covered with a phase change material lauric acid; drug-loaded nanoparticles are adhered to the lauric acid, and the drug-loaded nanoparticles are wrapped by polydopamine.
[0025] Specifically, when preparing the above-mentioned balloon, the following steps are included:
[0026] S1: 19 ml of Tris-HCl buffer solution (9 mM, pH = 8.5) was taken, and 50 mg of dopamine hydrochloride was added, then placed in a balloon and stirred in the dark for 23 hours, washed with ethanol three times and freeze-dried to obtain a polydopamine-coated balloon (PDA balloon);
[0027] S2: Take 19 ml of anhydrous ethanol and add 199 mg of lauric acid, then add the polydopamine-coated balloon and stir at room temperature for 23 hours to obtain a lauric acid-polydopamine balloon (LA-PDA balloon);
[0028] S3: The drug-loaded nanoparticles wrapped with polydopamine were adhered to the outermost layer of the lauric acid-polydopamine balloon by dip coating.
[0029] Example 2
[0030] This embodiment provides a balloon with near infrared response, efficient delivery and controlled release of drugs.
[0031] The invention comprises a base balloon; the surface of the balloon has a coating formed of polydopamine, and the polydopamine coating is formed on the surface of the balloon through an oxidative self-polymerization reaction; the polydopamine coating is further covered with a phase change material lauric acid; drug-loaded nanoparticles are adhered to the lauric acid, and the drug-loaded nanoparticles are wrapped by polydopamine.
[0032] Specifically, when preparing the above-mentioned balloon, the following steps are included:
[0033] S1: 20 ml of Tris-HCl buffer solution (10 mM, pH = 8.5) was taken, and 60 mg of dopamine hydrochloride was added, then placed in a balloon and stirred in the dark for 24 hours, washed with ethanol three times and freeze-dried to obtain a polydopamine-coated balloon (PDA balloon);
[0034] S2: Take 20 ml of anhydrous ethanol and add 200 mg of lauric acid, then add the polydopamine-coated balloon and stir at room temperature for 24 hours to obtain a lauric acid-polydopamine balloon (LA-PDA balloon);
[0035] S3: The drug-loaded nanoparticles wrapped with polydopamine were adhered to the outermost layer of the lauric acid-polydopamine balloon by dip coating.
[0036] Example 3
[0037] This embodiment provides a balloon with near infrared response, efficient delivery and controlled release of drugs.
[0038] The invention comprises a base balloon; the surface of the balloon has a coating formed of polydopamine, and the polydopamine coating is formed on the surface of the balloon through an oxidative self-polymerization reaction; the polydopamine coating is further covered with a phase change material lauric acid; drug-loaded nanoparticles are adhered to the lauric acid, and the drug-loaded nanoparticles are wrapped by polydopamine.
[0039] Specifically, when preparing the above-mentioned balloon, the following steps are included:
[0040] S1: 21 ml of Tris-HCl buffer solution (11 mM, pH = 8.5) was taken, and 70 mg of dopamine hydrochloride was added, then placed in a balloon and stirred in the dark for 25 hours, washed with ethanol three times and freeze-dried to obtain a polydopamine-coated balloon (PDA balloon);
[0041] S2: Take 21 ml of anhydrous ethanol and add 201 mg of lauric acid, then add the polydopamine-coated balloon and stir at room temperature for 25 hours to obtain a lauric acid-polydopamine balloon (LA-PDA balloon);
[0042] S3: The drug-loaded nanoparticles wrapped with polydopamine were adhered to the outermost layer of the lauric acid-polydopamine balloon by dip coating.
[0043] 1. Research on near-infrared light response
[0044] PDA balloons were prepared after treatment with dopamine hydrochloride at different concentrations, and near-infrared light heating experiments (808nm, 0.84W / cm2) were performed.
[0045] 2. Study on drug withdrawal rate
[0046] First, the drug shedding rate of the balloon before reaching the target site was explored through a vascular phantom, and then the concept was further verified through animal experiments.
[0047] 3. Results Analysis
[0048] As shown in Figure 1, the successfully modified balloon was verified using a scanning electron microscope. From the figure, it can be seen that the surface of the balloon is coated with polydopamine microspheres (Figure A), and its surface morphology is significantly changed after being coated with lauric acid (Figure B), and an obvious multilayer structure can be seen (Figure C).
[0049] In addition, the temperature-increasing ability of this near-infrared light-responsive multilayer drug-coated balloon under near-infrared (808 nm, 0.84 W / cm2) irradiation was also recorded, and the results showed that the balloon had excellent photothermal properties, such as Figure 2 and Figure 3 shown.
[0050] The present invention modifies the traditional drug balloon by using highly biocompatible materials polydopamine and lauric acid, and attaches polydopamine, lauric acid and drug-loaded nanoparticles layer by layer on the balloon surface. Among them, polydopamine is the main component of the sticky protein of mussel byssus, and has extremely strong adhesion properties; the phase change material lauric acid falls off from the balloon surface after being heated, and the balloon is modified to have the characteristics of zero drug loss and controllable complete release.
[0051] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments or to make equivalent substitutions for some of the technical features therein. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A balloon with near infrared response, efficient delivery and controlled release of drugs, characterized by: including a base balloon; The surface of the balloon has a coating formed of polydopamine, and the polydopamine coating is formed on the surface of the balloon through an oxidative self-polymerization reaction; The polydopamine coating is further coated with a phase change material, lauric acid; Drug-loaded nanoparticles are adhered to the lauric acid, and the drug-loaded nanoparticles are wrapped by polydopamine.
2. A method for preparing the balloon according to claim 1, characterized in that: The steps include: S1: Take a Tris-HCl buffer solution, add dopamine hydrochloride, put it into the balloon and stir it, wash it with ethanol and freeze-dry it to obtain a polydopamine coated balloon; S2: adding lauric acid to anhydrous ethanol, and then adding the polydopamine-coated balloon and stirring to obtain a lauric acid-polydopamine balloon; S3: The drug-loaded nanoparticles wrapped with polydopamine were adhered to the outermost layer of the lauric acid-polydopamine balloon by dip coating.
3. The method according to claim 2, characterized in that: In S1, the Tris-HCl buffer solution is 19-21 ml.
4. The method according to claim 2, characterized in that: In S1, the Tris-HCl buffer solution is 9-11 mM, pH=8.
5.
5. The method according to claim 2, characterized in that: In S1, dopamine hydrochloride is 50-70 mg.
6. The method according to claim 2, characterized in that: In S1, the stirring condition is stirring in the dark for 23-25 hours.
7. The method according to claim 2, characterized in that: In S1, the number of ethanol washes was 3 times.
8. The method according to claim 2, characterized in that: In S2, anhydrous ethanol is 19-21 ml.
9. The method according to claim 3, characterized in that: In S2, lauric acid was 199-201 mg.
10. The method according to claim 3, characterized in that: In S2, the stirring condition is stirring at room temperature for 23-25 hours.
Citation Information
Cited By
Phase change eutectic carrier embedded with photo-thermal agent as well as preparation method and application of phase change eutectic carrier
CN119817573A
